P3+ Intervention Phase
NCT02898688 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 2200
Last updated 2020-08-05
Summary
This study will address vaccine uptake both for pregnant women and for their children, through 20 months of age, to test the hypothesis that exposure to the P3+ intervention package will increase the likelihood a pregnant woman gets herself vaccinated against influenza and pertussis before delivery and get her child vaccinated on time. This study builds off of a prior intervention, developed by Emory, at the practice, provider, and patient levels (P3) to develop, implement and evaluate an enhanced intervention (P3+) to improve vaccination uptake among pregnant women, and later, their children.
Conditions
- Vaccination
Interventions
- BEHAVIORAL
-
Control Site
Control sites will continue with their standard practice regarding discussing vaccines with their patients.
- BEHAVIORAL
-
Intervention Site
Intervention Sites will each assign a Vaccine Champion and will have Assessment, Feedback, Incentives, and eXchange (AFIX) visits. AFIX is a quality improvement program to raise immunization coverage levels, reduce missed opportunities to vaccinate, and improve standards of practices at the provider level. A Continuing Medical Education (CME) module will be given to all providers, covering the recommended maternal vaccinations and how to talk to patients about vaccines. Intervention sites will have access to written materials covering all recommended maternal and infant vaccinations, the diseases they prevent, potential adverse reactions and common patient questions with talking points and references for each topic.
- BEHAVIORAL
-
Patient-level Control Group
Participants randomized the control arm will complete a computer-based questionnaire, on an iPad with a preloaded app. The questionnaire asks about vaccine knowledge, attitudes, and beliefs and the participant's intent to receive vaccinations during pregnancy and to vaccinate their baby. The questionnaire includes questions requiring a "yes" or "no" response, degree of agreement with vaccine-related statements (ranging from strongly agree to strongly disagree), questions to capture the vaccines participants plan to get for themselves and their children, and open-ended questions.
- BEHAVIORAL
-
Patient-level Intervention Group
Participants randomized to the intervention arm will complete a computer-based questionnaire on an iPad with a preloaded app, prior to watching informational videos covering topics on maternal and childhood vaccines. The questionnaire asks about vaccine knowledge, attitudes, beliefs, and the participant's intent to receive vaccinations during pregnancy and to vaccinate their baby. The questions require "yes" or "no" responses, degree of agreement with vaccine-related statements (ranging from strongly agree to strongly disagree), and open-ended responses. After watching at least one informational video, the participant completes a questionnaire asking about the perceived usefulness of the app, degree of agreement with the vaccine information presented in the video, and ways to make the app more useful to participants.
Sponsors & Collaborators
-
National Institute of Allergy and Infectious Diseases (NIAID)
collaborator NIH -
Emory University
lead OTHER
Principal Investigators
-
Robert Bednarczyk, PhD · Emory University
-
Daniel Salmon, PhD, MPH · Johns Hopkins Bloomberg School of Public Health
Study Design
- Allocation
- RANDOMIZED
- Purpose
- HEALTH_SERVICES_RESEARCH
- Masking
- NONE
- Model
- FACTORIAL
Eligibility
- Min Age
- 18 Years
- Max Age
- 50 Years
- Sex
- FEMALE
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2017-06-12
- Primary Completion
- 2020-07-06
- Completion
- 2020-07-06
Countries
- United States
Study Locations
More Related Trials
-
PreTeenVax Evaluation
NCT03186430 ·Status: COMPLETED ·Phase: NA
-
Study Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC)
NCT00546572 ·Status: COMPLETED ·Phase: PHASE3
-
Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Infants
NCT00366899 ·Status: COMPLETED ·Phase: PHASE3
-
Pneumonia Vaccine Education Intervention Study
NCT06136832 ·Status: COMPLETED ·Phase: NA
-
Study to Evaluate the Safety and Immunogenicity of an Investigational Pneumococcal Vaccine in the Elderly Population
NCT00327665 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Learn About How a New Pneumococcal Vaccine Works in Children
NCT06531538 ·Status: COMPLETED ·Phase: PHASE2
-
Study Evaluating 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants in Mexico
NCT00708682 ·Status: COMPLETED ·Phase: PHASE3
-
Study Evaluating Antibody Response Of 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) 24 Months After Toddler Dose.
NCT01026038 ·Status: COMPLETED ·Phase: PHASE3
-
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine
NCT00345358 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)
NCT03547167 ·Status: COMPLETED ·Phase: PHASE3
-
A Study Evaluating 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) In Healthy Infants In China
NCT01692886 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants
NCT00366678 ·Status: COMPLETED ·Phase: PHASE3
-
Protecting From Pneumococcus in Early Life (The PROPEL Trial)
NCT02628886 ·Status: UNKNOWN ·Phase: PHASE3
-
Study Evaluating 13 Valent Pneumococcal Conjugate Vaccine With Trivalent Inactivated Influenza Vaccine
NCT00521586 ·Status: COMPLETED ·Phase: PHASE3
-
20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 4-Dose Series in Healthy Infants
NCT04382326 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Learn About a Type of Pneumococcal Vaccine With a New Ingredient (PF-07872411) Intended to Enhance the Effects of the Vaccine Which is Given to Adults
NCT05831124 ·Status: COMPLETED ·Phase: PHASE1
-
Impact of GSK Biologicals' 2189242A Vaccine on Nasopharyngeal Carriage, Safety & Immunogenicity in Children & Infants
NCT01262872 ·Status: COMPLETED ·Phase: PHASE2
-
Phase III Clinical Trial of 13-valent Pneumococcal Conjugate Vaccine (Multivalent Conjugate) in Infants
NCT05759520 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Study Evaluating Safety of 13-Valent Pneumococcal Conjugate Vaccine in Healthy Elderly Subjects
NCT00500266 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants
NCT00384059 ·Status: COMPLETED ·Phase: PHASE3
-
Study Comparing 13-valent Pneumococcal Conjugate Vaccine With 7-valent Pneumococcal Conjugate Vaccine
NCT00373958 ·Status: COMPLETED ·Phase: PHASE3
-
Study Evaluating the Safety, Tolerability and Immunogenicity of 13vPnC as a 2-Dose Regimen or With 23vPS
NCT00574548 ·Status: COMPLETED ·Phase: PHASE3
-
Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Elderly Subjects
NCT00500357 ·Status: COMPLETED ·Phase: PHASE3
-
Trial to Evaluate the Safety and Immunogenicity of 3 Lots of 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults
NCT03828617 ·Status: COMPLETED ·Phase: PHASE3
-
Phase I to Test a New Pneumococcal Vaccine
NCT03303976 ·Status: COMPLETED ·Phase: PHASE1